Fennec Pharmaceuticals Inc. (FRX)
Summary
FRX Chart
Can Adherex Technologies (FENC) Climb 26.53% to Reach the Level Wall Street Analysts Expect?
The mean of analysts' price targets for Adherex Technologies (FENC) points to a 26.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Adherex Technologies Q2 Earnings Call Highlights
Adherex Technologies NASDAQ: FENC, operating as Fennec Pharmaceuticals, reported second-quarter 2026 net product sales of $17.1 million, up approximately 78% from $9.7 million in the prior-year period, as demand for its PEDMARK therapy continued to rise.
Adherex Technologies Inc. (FENC) Beats Q2 Earnings and Revenue Estimates
Adherex Technologies Inc. (FENC) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to a loss of $0.11 per share a year ago.
Fennec Pharmaceuticals Inc. (FRX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Fennec Pharmaceuticals Inc. ever had a stock split?
Fennec Pharmaceuticals Inc. Profile
| Biotechnology Industry | Healthcare Sector | Jeffrey S. Hackman CEO | NEO-L Exchange | CA31447P1009 ISIN |
| US Country | 35 Employees | - Last Dividend | 31 Aug 2011 Last Split | 5 Jun 2001 IPO Date |
Overview
Fennec Pharmaceuticals Inc. is a prominent biopharmaceutical company based in the United States, engaged in the development and commercialization of specialized therapies. Originally established as Adherex Technologies Inc., the company underwent a significant rebranding in September 2014, adopting the name Fennec Pharmaceuticals Inc. This rebranding reflects its evolution and dedicated focus on addressing specific medical needs. Since its inception in 1996, Fennec Pharmaceuticals has positioned itself in the Research Triangle Park, North Carolina, leveraging the region's rich resources in research and development. The company primarily targets pediatric cancer patients, aiming to mitigate the adverse effects associated with platinum-based chemotherapy treatments.
Products and Services
-
PEDMARK:
This leading product candidate by Fennec Pharmaceuticals Inc. is a novel formulation of sodium thiosulfate designed specifically for the prevention of platinum-induced ototoxicity in pediatric cancer patients. Platinum-based chemotherapies, while effective in treating cancer, often come with the severe side effect of ototoxicity—damage to the ear that can result in hearing loss. PEDMARK represents a significant advancement in the care and quality of life for young cancer patients, addressing an unmet need in pediatric oncology. The distribution of this product is strategically implemented through collaborations with regional pediatric oncology specialists and medical science liaisons, ensuring that the benefits of PEDMARK reach the patients in need effectively.
